Sponsor content
13 result(s) found, displaying 11 to 13
-
Prescription medicine decision summaryTGA decision: VYXEOS (daunorubicin and cytarabine) is approved to treat therapy-related acute myeloid leukaemia and AML-MRC.
-
Prescription medicine registrationActive ingredients: daunorubicin hydrochloride, cytarabine.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Sativex Oromucosal Spray, nabiximols 80 mg/mL pump actuated metered dose aerosol.